Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Virus-Cell Interactions

Differential CD4/CCR5 Utilization, gp120 Conformation, and Neutralization Sensitivity between Envelopes from a Microglia-Adapted Human Immunodeficiency Virus Type 1 and Its Parental Isolate

Julio Martı́n, Celia C. LaBranche, Francisco González-Scarano
Julio Martı́n
Departments of Neurology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Celia C. LaBranche
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco González-Scarano
Departments of Neurology and
Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.75.8.3568-3580.2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Microglial infection. Human adult microglial cultures were established as previously described (1, 2, 95, 116) and infected with 5 ng/ml p24gag of supernatants containing env-pseudotyped, luciferase viruses. After 48 to 62 h, cells were lysed and the extent of infection was measured by the intensity of chemiluminescence when mixing equal volumes of substrate and cell lysate. A representative experiment (performed in triplicate) is shown, and the results are expressed as the mean + standard deviation (error bars).

  • Fig. 2.
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Effect of sCD4 on infection of cells expressing CCR5 alone or with CD4. (A) HOS cells stably transfected for the expression of CD4 (HOS-CD4), CCR5 (HOS-CCR5), or both (HOS-CD4-CCR5) were infected with supernatants containing env-pseudotyped, luciferase viruses (p24gag [5 ng/ml]). The results are expressed as the mean + standard deviation (error bars) from four independent experiments each performed in triplicate. (B) Treatment with sCD4 (5 μg/ml) inhibited infection of HOS-CD4-CCR5 cells by rB15 and rV1V2 but not by rBORI pseudotypes. Results are shown as percent luciferase activity relative to the value in the absence of sCD4 treatment, in four independent experiments each performed in triplicate. The differences in values between rBORI and rB15 or rV1V2 were statistically significant (Wilcoxon's rank-sum test: P < 0.05 in both cases).

    • Open in new tab
    • Download powerpoint
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Infection of cells expressing decreasing amounts of CD4 and/or CCR5. U87 cells were transiently transfected with plasmids expressing CD4 and CCR5 and subsequently infected with supernatants containing env-pseudotyped, luciferase viruses (p24gag [5 ng/ml]). (A) rBORI pseudotype did not infect cells expressing low CD4 and high CCR5 or low CD4/CCR5, while rB15 and rV1V2 did. Results are expressed as the mean + standard deviation (error bars) from seven independent experiments each performed in triplicate. (B) The luciferase activity measured following infection of low-CD4 and high-CCR5 or low-CD4/CCR5 cells was expressed as a percentage of the activity induced in the high-CD4/CCR5 cells. We performed seven independent experiments with the rBORI, rB15, and rV1V2 pseudotypes. The differences in the values between rBORI and rB15 or rV1V2 were statistically significant (Wilcoxon's rank-sum test: P < 0.01 in both comparisons for low CD4 and high CCR5 and for low CD4/CCR5).

  • Fig. 4.
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Infection of cells expressing CD4 and the 5552 or Δ4 chimeric coreceptors. U87 cells were transiently transfected with plasmids expressing CD4 and the chimeric coreceptors 5552 (amino terminus, ECL1 and ECL2 of CCR5, and ECL3 of CCR2b) or Δ4 (deletion of the first four amino acids in the amino terminus of CCR5), and subsequently infected with supernatants containing env-pseudotyped, luciferase viruses (p24gag [5 ng/ml]). Luciferase activity is shown as the percentage with respect to wild-type CCR5 for each virus and experiment. Horizontal lines represent the median of each group of data. For the 5552 chimera, rBORI infections were significantly less efficient than rB15 and rV1V2 infections (Wilcoxon's rank-sum test: P < 0.001 in both cases). For the Δ4 mutant, rBORI infected significantly less than rB15 and rV1V2 ( P < 0.01 and P < 0.02 , respectively).

  • Fig. 5.
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Neutralization with HIV-1-positive human sera. A MAGI-CCR5 cell-based, single-cycle infection assay was performed as described in Materials and Methods, to test the neutralization sensitivity of VH-rBORI, VH-rB15, and VH-rV1V2 recombinant viruses (93) either in the presence of a 1/10 dilution of NHS or in the presence of increasing dilutions of serum from four HIV-1-infected individuals. Results were calculated as percentage of infection with respect to the extent observed with virus plus NHS, and the values shown represent the average of two to three independent experiments.

  • Fig. 6.
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    17b ELISA and neutralization assays. (A) An ELISA was performed using the 17b MAb with supernatants containing env pseudotypes, either with or without sCD4. Results are shown as mean optical density at 405 nm + standard error of the mean (error bars) from four independent experiments using different pseudotype stocks. Absent sCD4, reactivity with the 17b antibody was greater in rB15 and rV1V2 than in rBORI pseudotypes (Student's t test: P < 0.02 and P < 0.05 , respectively). (B) 17b MAb neutralization was performed in U87 cells transiently transfected with CD4-CCR5 (left; four independent experiments) and in microglial cultures (right; three independent experiments with two microglial preparations). The pseudotypes were incubated with 17b MAb (20 μg/ml) at 37°C for 1 h prior to inoculation. Data are shown as percentage of luciferase activity with respect to untreated controls for each pseudotype. In both cell types, 17b inhibited infection by rB15 and rV1V2 pseudotypes but not by rBORI.

Tables

  • Figures
  • Table 1.

    Amino acid differences and syncytium-inducing phenotype, in the context of whole or recombinant viruses, of envused for the production of pseudotypes

    env-pseudotyped virusAmino acid differences with respect to BORI or rBORINo. of potential N-linked glycosylation sites lostSyncytium-inducing phenotype
    No.Amino acid change(s) and positiona
    BORI00Noninducing
    rBORI00Noninducing
    B158E153G, T162Ab, R166G, S190Rb, K229N, T281I, A336T, V532M2High
    rB158E153G, T162Ab, R166G, S190Rb, K229N, T281I, A336T, V532M2High
    rV1V24E153G, T162Ab, R166G, S190Rb 2High
    rE153G1E153G0High
    rE153G,T162A2E153G, T162Ab 1Noninducing
    • ↵a Numbers are based on the HXB2 sequence. BORI and B15 contain HXB3 sequences at both the carboxy and amino termini, as discussed in Materials and Methods and by Shieh et al. (93).

    • ↵b Change results in the loss of a potential N-linked glycosylation site.

  • Table 2.

    Infection of U87 cells expressing CD4 and the indicated chimeric coreceptor by env-pseudotyped, luciferase viruses

    CoreceptorMean luciferase activity ± SD (RLU/s)a
    rBORIrB15RV1V2rE153GrE153G, T162A
    None132 ± 68195 ± 112281 ± 161141 ± 64149 ± 59
    CCR5 b 24,611 ± 11,755 75,090 ± 15,932 108,548 ± 25,902 42,948 ± 16,214 38,309 ± 15,001
    CCR2b98 ± 35187 ± 137250 ± 70192 ± 84171 ± 64
    5222643 ± 5901,509 ± 1,2252,413 ± 2,3561,414 ± 769938 ± 1,356
    252274 ± 3979 ± 38119 ± 5560 ± 4872 ± 51
    225271 ± 3375 ± 4179 ± 1154 ± 2272 ± 33
    2225101 ± 61107 ± 55269 ± 21686 ± 3777 ± 21
    2555735 ± 904614 ± 513792 ± 573208 ± 226361 ± 356
    52558,604 ± 4,53928,211 ± 13,61749,532 ± 14,62313,489 ± 4,55312,803 ± 6,802
    5525587 ± 3992,284 ± 2,1694,519 ± 2,1912,101 ± 1,485688 ± 593
    5552 1,071 ± 814 15,960 ± 6,144 26,984 ± 8,637 5,845 ± 2,832 4,231 ± 3,273
    52522,912 ± 1,2699,104 ± 3,59919,053 ± 11,0733,892 ± 1,6207,640 ± 4,246
    Δ4 1,734 ± 1,025 12,501 ± 8,077 18,904 ± 11,742 2,731 ± 3,092 4,250 ± 3,338
    Δ81,545 ± 1,0232,442 ± 1,9903,780 ± 2,2273,362 ± 1,8491,435 ± 1,603
    Δ12134 ± 11291 ± 3863 ± 1862 ± 1759 ± 21
    Δ16122 ± 10889 ± 4149 ± 2247 ± 2665 ± 26
    • ↵a Luciferase activity is calculated from 5 to 17 independent experiments performed at least in triplicate.

    • ↵b Values in bold represent statistical significant changes in comparison with wild-type CCR5, also in bold, as indicated in the text.

PreviousNext
Back to top
Download PDF
Citation Tools
Differential CD4/CCR5 Utilization, gp120 Conformation, and Neutralization Sensitivity between Envelopes from a Microglia-Adapted Human Immunodeficiency Virus Type 1 and Its Parental Isolate
Julio Martı́n, Celia C. LaBranche, Francisco González-Scarano
Journal of Virology Apr 2001, 75 (8) 3568-3580; DOI: 10.1128/JVI.75.8.3568-3580.2001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Differential CD4/CCR5 Utilization, gp120 Conformation, and Neutralization Sensitivity between Envelopes from a Microglia-Adapted Human Immunodeficiency Virus Type 1 and Its Parental Isolate
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Differential CD4/CCR5 Utilization, gp120 Conformation, and Neutralization Sensitivity between Envelopes from a Microglia-Adapted Human Immunodeficiency Virus Type 1 and Its Parental Isolate
Julio Martı́n, Celia C. LaBranche, Francisco González-Scarano
Journal of Virology Apr 2001, 75 (8) 3568-3580; DOI: 10.1128/JVI.75.8.3568-3580.2001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

CD4 Antigens
HIV Envelope Protein gp120
HIV-1
microglia
Receptors, CCR5

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514